Table 2.
Association between disclosure of PrEP use by month three and PrEP adherence at months three and six
| Disclosed PrEP use by 3 months | Increase DBS TFV-DP | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month three adherencea | Month six adherencea | ||||||||
| N = 349 | Mean (95%CI) | fmol/punch (95% CI) | T test | P value | Mean (95%CI) | fmol/punch (95% CI) | T test | P value | |
| Anyone | 309 (89%) | 431 (387, 474) | − 18 (− 153, 114) | − 0.28 | 0.78 | 368 (307, 429) | 77 (− 97, 251) | 0.87 | 0.38 |
| Parents | 251 (72%) | 441 (401, 497) | 84 (− 16, 184) | 1.64 | 0.10 | 375 (310, 440) | 96 (− 35, 228) | 1.46 | 0.15 |
| Sexual partners | 265 (76%) | 434 (387, 482) | 8 (− 96, 113) | 1.16 | 0.88 | 381 (314,448) | 102 (− 34, 237) | 1.46 | 0.15 |
| Friends | 287 (82%) | 436 (391, 481) | 21 (− 98, 141) | 0.33 | 0.74 | 363 (300, 427) | 56 (− 102, 215) | 0.69 | 0.49 |
DBS TFV-DP tenofovir-diphosphate concentrations in dried blood spots, CI confidence interval
aAdjusted for site and age